Cingulate Inc. filed a Form 8-K on November 10, 2026, disclosing the status of its CTx-1301 new drug application resubmission following an FDA Complete Response Letter, with a resubmission window targeted between December 2026 and January 2027.

Key Highlights

  • FDA Complete Response Letter received: Cingulate received a CRL from the FDA on June 1, 2026, regarding the NDA for CTx-1301.
  • CRL limited to CMC issues: According to the filing, the CRL identified specific requests for additional chemistry, manufacturing and controls (CMC) information and "did not raise any concerns regarding the clinical safety or efficacy of CTx-1301."
  • Manufacturing work substantially complete: The company and its contract drug manufacturing organization have "substantially completed the manufacturing work required to address the CMC requests in the CRL."
  • Resubmission targeted for December 2026 to January 2027: The company disclosed it currently expects to submit the NDA resubmission within that window.
  • Potential commercial launch in Q3 2027: Subject to FDA approval, the company currently expects that commercial launch of CTx-1301 "could commence in the third quarter of 2027."
  • CEO media appearance: Chairman and CEO Shane J. Schaffer discussed the FDA response and resubmission timeline in an interview on Innovators with Jane King.

Cingulate Discloses CTx-1301 Resubmission Timeline After FDA's CMC-Only CRL

Cingulate Inc. (NASDAQ:CING) reported in its November 10, 2026 Form 8-K that it is working to resubmit its new drug application for CTx-1301 after receiving a Complete Response Letter from the FDA on June 1, 2026. The filing noted that the FDA's original targeted action date under the Prescription Drug User Fee Act had been May 31, 2026, following the agency's acceptance of the NDA for review in October 2025.

According to the filing, the CRL was confined to chemistry, manufacturing and controls matters and did not raise clinical safety or efficacy concerns. The company disclosed that it and its contract drug manufacturing organization have substantially completed the manufacturing work needed to respond, and are finalizing supporting data and documentation. The company currently expects to submit the resubmission between December 2026 and January 2027, though the filing states there can be no assurance regarding the timing or occurrence of the submission.

The filing explained that upon receipt of a resubmission, the FDA is expected to classify it as either a Class 1 or a Class 2 resubmission, carrying review goals of two months and six months, respectively. Subject to approval, the company currently expects commercial launch of CTx-1301 could begin in the third quarter of 2027. The filing includes multiple cautionary statements that there can be no assurance of resubmission, FDA classification, acceptance, approval, or commercial launch timing. The disclosures were furnished under Regulation FD and Item 8.01 of the Form 8-K.

What Was Disclosed

Cingulate Inc. disclosed the status of its CTx-1301 NDA resubmission effort following an FDA Complete Response Letter limited to CMC issues, a targeted resubmission window of December 2026 to January 2027, and an anticipated commercial launch in the third quarter of 2027, subject to FDA approval.